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Abstract
For two centuries, vaccination has been the dominating approach to develop prophylaxis against
viral infections through immunological prevention. However, vaccines are not always possible to
make, are ineffective for many viral infections, and also carry certain risk for a small, yet significant
portion of the population. In the recent years, FDA's approval and subsequent market acceptance
of Synagis, a monoclonal antibody indicated for prevention and treatment of respiratory syncytial
virus (RSV) has heralded a new era for viral infection prevention and treatment. This emerging
paradigm, herein designated "Biochemical Prevention and Treatment", currently involves two
aspects: (1) preventing viral entry via passive transfer of specific protein-based anti-viral molecules
or host cell receptor blockers; (2) inhibiting viral amplification by targeting the viral mRNA with
anti-sense DNA, ribozyme, or RNA interference (RNAi). This article summarizes the current
status of this field.
Introduction
A landmark in the battle against viral infectious diseases
was made in 1798 when Jenner first inoculated humans
against smallpox with the less virulent cowpox. For about
two centuries since then, humans relied almost exclu-
sively on vaccines for protection against viruses. Only in
the recent years, new strategies for controlling viral infec-
tious diseases have emerged, which have so far led to a
couple of viral prophylaxis/therapeutics on the market.
These strategies are fundamentally different from vaccines
in that they attempt to directly interrupt viral infectious
life cycle at molecular level by using proteins or oligonu-
cleotides. To differentiate them from the conventional
vaccines that prevent viral infection by boosting immune
system, we refer the new antiviral approaches as "Bio-
chemical Prevention and Treatment" (see figure 1). Bio-
chemical Prevention and Treatment, as an alternative to
vaccines and chemical compound based antiviral drugs,
may prove to be particularly valuable in the areas where
vaccines and/or chemical drugs can not be generated or
have not been successful in human, including diseases
caused by some common pathogenic viruses, such as HIV,
hepatitis C virus (HCV), RSV and human rhinovirus
(HRV). In this review, we will discuss various molecular
intervention approaches.
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Among the biochemical therapeutics currently in clinical
trials, the majority consists of monoclonal antibodies
(MAbs). Soluble receptor drug candidates have gradually
lost favor over the past several years due to issues relating
to low potency and cost. Peptide-based drug candidates
are limited by insufficient efficacy and unfavorable phar-
macokinetics. MAbs have increasingly gained favor in
large part because of the development of chimeric,
humanized, and human antibodies have reduced the
immunogenicity of antibody therapies. The MAbs that are
currently in clinical trials for viral infection prophylaxis
and treatment are listed in Table 1.
Biochemical Prevention and Treatment of Respiratory Syncytial Virus 
Infection
The respiratory syncytial virus (RSV) is a major cause of
lower respiratory tract infection in infants and young chil-
dren producing bronchiolitis and pneumonia worldwide.
RSV infection leads to more than 90,000 hospitalizations
and a 2% mortality rate among infants nationwide [2-5].
Approximately two-thirds of infants are infected with RSV
during the first year of life and approximately 95% of
children test seropositive for RSV by the age of two [6].
Unfortunately, even natural RSV infection produces lim-
ited immunity at best. In fact, an inactivated RSV vaccine
paradoxically resulted in more severe disease instead of
protection [7].
The most successful approach to date has been Biochemi-
cal Prevention and Treatment with anti-viral antibodies.
In 1996, RespiGam™ (respiratory syncytial virus immune
Targets of different Biochemical Prevention and Treatment strat giesFigure 1
Targets of different Biochemical Prevention and 
Treatment strategies. Antibodies (Ab) or soluble recep-
tors (Rc) can inhibit the viral entry. Antisense oligonucle-
otides (AS-ONs), ribozymes (Rz) or siRNA (SI) pair with 
their complementary target genomic DNA, RNA or mRNA. 
AS-ONs can block recombination, transcription, translation 
of the mRNA or induce its degradation by RNaseH. Rz pos-
sess catalytic activity and cleave their targets. SiRNAs (SI) 
induce degradation of the target mRNA via RNA-induced 
silencing complex (RISC).
Table 1: Monoclonal Antibodies in Clinical Trials
Product Company Disease Status
MEDI-501 MedImmune Genital Warts HPV II
Nabi-HB Nabi Biopharmaceuticals Hepatitis B Market
Ostavir Protein Design Labs Hepatitis B II
XTL-002 XTL Biopharmaceuticals Ltd. Hepatitis C I
Civacir Nabi Biopharmaceuticals Hepatitis C I/II
1F7 Antibody Immune Network Ltd. Hepatitis C, HIV/AIDS Preclinical
PRO 140 Progenics Pharmaceuticals HIV/AIDS Preclinical
hNM01 AbNovo Inc., Immune Network Ltd. HIV/AIDS I
PRO 367 Roche Holding Progenics Pharmaceuticals HIV/AIDS I/II
TNX-355 Tanox, Inc., Biogen, Inc. (Massachusetts) HIV/AIDS I
OraQuick HIV-1 OraSure Technologies, Inc. HIV/AIDS Market
Cytolin CytoDyn Amerimmune Pharmaceuticals, Inc. HIV/AIDS I/II
Tipranavir TIPRANAVIR HIV/AIDS III
HXB AAI International, AnaaiPharma Company Herpes Simplex Virus type 2 Preclinical
MEDI-491 MedImmune Human B19 parvovirus I
Synagis™ (Palivizumab) MedImmune Respiratory Syncytial Virus Approved in 1998
Numax MedImmune Respiratory Syncytial Virus Preclinical
INS37217 Intranasal Inspire Pharmaceuticals Rhinovirus (common cold) IIPage 2 of 6
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less than two years of age with high-risk factors [8-10]. The
use of RespiGam™ was largely supplanted with the
approval of Synagis™ (Palivizumab) in 1998. Palivizumab
is an IgG1 MAb administered IM monthly that selectively
binds to the RSV surface glycoprotein F [1,51]. The drug
specifically inhibits RSV replication by preventing the
virus from fusing with the respiratory endothelial cell
membrane. Palivizumab has been shown to reduce the
rate of hospitalization of at-risk infants by about 55% in
clinical studies and now serves as the primary medical
means of RSV prevention [11-13].
Prevention of Human Rhinovirus infections
Human rhinovirus (HRV) causes over 80% of the com-
mon cold in the fall [14]. Developing vaccines against
HRV is unfeasible because HRVs have at least 115 antigen-
ically distinct serotypes [15,16]. One of the proven meth-
ods to prevent and inhibit viral infections is to block host
cell receptors that are used by viruses to gain cell entry.
Receptor blockage is commonly achieved via application
of MAbs that bind to specific epitopes on the receptor
molecules. A plethora of in vitro studies have reported
effective viral inhibition by receptor-blocking MAbs.
However, these works have not yielded yet any approved
drug on the market.
In HRV infection, about 90% of HRV serotypes utilize a
single cell surface receptor exclusively, which is the inter-
cellular adhesion molecule-1 (ICAM-1), for viral attach-
ment and subsequent viral entry [17,18]. As such, ICAM-
1 has become a very promising target for biochemical pre-
vention. A receptor blocking approach has shown that the
soluble ICAM-1 and an anti-ICAM-1 monoclonal anti-
body, Mab 1A6, could prevent infections by a broad spec-
trum of rhinovirus serotypes in human cells in vitro [19-
21]. Administration of soluble ICAM-1 and MAbs in
human clinical trials had indeed achieved reduction in
symptoms, but did not prevent the incidence of the dis-
ease [22-24]. For the MAbs, the limited efficacy is most
likely due to its low functional affinity (or avidity) for
ICAM-1 when compared to that of the multivalent HRV
particles [25].
High avidity is achieved by multivalency. To improve
avidity of HRV receptor blocking antibody, a novel tetrav-
alent recombinant antibody, CFY196, has been generated
against ICAM-1 [26]. CFY196 is composed of Fab frag-
ment of a humanized version of MAb 1A6 fused with a
linker derived from human immunoglobulin D (IgD)
hinge and a tetramerization domain derived from the
coiled-coil sequence of human transcription factor ATFα.
CFY196 is expressed in bacteria and purified as a homog-
enous tetrameric molecular complex. CFY196 exhibited
almost two-orders-of-magnitude improvement in
functional affinity compared with its bivalent counterpart
based on the kinetic parameters measured by BIAcore
analysis. Such kinetic improvement also directly leads to
functional superiorities of CFY196. In in vitro assays,
CFY196 consistently and significantly outpaced the best
commercial anti-ICAM-1 MAbs in preventing HRV infec-
tion as measured by reduction of cytopathic effects and
HRV viral titers [26]. The preclinical findings of CFY196
bode well its efficacy in human since MAb 1A6, from
which CFY196 is derived, has already exhibited positive
effects in a human trial. Moreover, to prevent possible
immunogenicity, CFY196 is humanized [27]. Further pre-
clinical and clinical development of CFY196 is warranted
to fully evaluate its potential as a prophylaxis and thera-
peutics for the HRV induced common colds.
2. Biochemical Prevention and Treatment via targeting on 
viral mRNA
Targeting viral mRNA is one of the most active areas of
research and development. Several strategies have
emerged over the years and are being tested pre-clinically
and clinically. They include: antisense-oligonucleotides
(AS-ONs), ribozymes, and recently, RNA interference
(RNAi). All these strategies share the features of concep-
tual simplicity, straightforward drug design and quick
route to identify drug leads. However, the challenges have
been to improve potency, pharmacokinetics and, most
importantly, intracellular delivery of the drug candidates.
As the oldest strategy, AS-ON technology has produced to
date one drug in the market place, Vitravene®. A number
of clinical trials of drug candidates from these technolo-
gies are currently ongoing.
Antisense-oligonucleotides
Antisense-oligonucleotides (AS-ONs) are short synthetic
oligonucleotides that form complementary pair with spe-
cific viral mRNA targets. AS-ONs inhibit viral protein pro-
duction by both blocking viral mRNA translation and
triggering its degradation. Since the discovery of viral inhi-
bition effect of AS-ONs by Zamecnik and Stephenson in
1978 [28], antisense technology has been developed as a
powerful tool for target validation and therapeutic
purposes.
Vitravene is the first AS-ON based drug approved by FDA.
Vitravene, or fomivirsen sodium, is a 21-base phospho-
rothioate oligodeoxynucleotide complementary to the
messenger RNA of the major immediate-early region pro-
teins of human cytomegalovirus, and is a potent and
selective antiviral agent for cytomegalovirus retinitis, a
herpes-like eye disease that afflicts the immune-sup-
pressed [29,30]. A number of clinical trials as well as one
approved therapy based on AS-ON technologies are sum-
marized in Table 2.Page 3 of 6
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'first generation' DNA analogs. The 'second generation' ONs
contain nucleotides with alkyl modifications at the 2'
position of the ribose. They are less toxic than PS-DNAs
and have a slightly enhanced affinity. DNA and RNA ana-
logs with modified phosphate linkages, or different sugar
residues substituting the furanose ring have been referred
as 'third generation' [34]. For instance, peptide nucleic
acids and their analogs display superior sequence specifi-
city and are resistant to nuclease degradation. These third
generation AS-ON have limited non-specific interactions
with other genes and, therefore, have shown great poten-
tials in clinical trials.
Ribozymes
Ribozymes (Rz) are catalytically active ONs that both
bind and cleave target RNAs. They were discovered after
the AS-ON technology. Initial findings on ribozymes
raised the hope that they may offer a more potent alterna-
tive to AS-ONs. Many cell based and animal tests have
performed on anti-viral effects of ribozymes, including
HIV, hepatitis B, hepatitis C, influenza, etc. Results from
these tests have shown that ribozymes are promising viral
inhibitors [35-38]. However, further progress in the field
has been hampered by difficulties to achieve satisfactory
potency and efficient intracellular delivery of ribozymes
in vivo. HEPTAZYME is a modified ribozyme that cleaves
the internal ribosome entry site of the Hepatitis C virus.
The Rz was demonstrated to inhibit viral replication up to
90% in cell culture [39]. HEPTAZYME was tested in a
Phase II clinical trial, but was later withdrawn from fur-
ther clinical trials due to insufficient efficacy. So far, there
is no anti-viral ribozymes that are being actively tested in
advanced clinical trials.
RNA Interference (RNAi)
RNA interference, or RNAi, is the inhibition of expression
of specific genes by double-stranded RNAs (dsRNAs). It is
becoming the method of choice to knockdown gene
expression rapidly and robustly in mammalian cells.
Comparing to the traditional antisense method, RNAi
technology has the advantage of significantly enhanced
potency; therefore, only lower concentrations may be
needed to achieve same level of gene knockdown. RNAi
gained rapid acceptance by researchers after Tuschl and
coworkers discovered that in vitro synthesized small
interfering RNAs (siRNAs) of 21 to 23 nucleotides in
length can effectively silence targeted genes in mamma-
lian cells without triggering interferon production
[40,41]. In mammalian cells, the level of gene inhibition
mediated by siRNA routinely reaches an impressive 90%
[42].
Several initial studies, which test the potential application
of synthetic siRNAs as antiviral agents, have shown very
promising results. To date, RNAi has been used effectively
Table 2: Clinical trials and an approved therapy based on AS-ON technologies [31-33].
Product Company Target Disease Chemistry Status
Vitravene (Fomivirsen) ISIS Pharmaceuticals CMV IE2 CMV retinitis PS DNA Approved in 1998
Affinitac (ISIS 3521) ISIS PKC-α Cancer PS DNA Phase III
Genasense Genta Bcl2 Cancer PS DNA Phase III
Alicaforsen (ISIS 2302) ISIS ICAM-1 Psoriasis, Crohn's disease, Ulcerative 
colitis
PS DNA Phase II/III
ISIS 14803 ISIS Antiviral Hepatitis C PS DNA Phase II
ISIS 2503 ISIS H-ras Cancer PS DNA Phase II
MG98 Methylgene DNA methyl 
transferase





Asthma PS DNA Phase II
GTI 2040 Lorus Therapeutics Ribonucleotide 
reductase (R2)
Cancer PS DNA Phase II
ISIS 104838 ISIS TNFα Rheumatoid Arthritis, Psoriasis 2nd generation Phase II
Avi4126 AVI BioPharma c-myc Restenosis, cancer, Polycystic kidney 
disease
3rd generation Phase I/II
Gem231 Hybridon PKA RIα Solid tumors 2nd generation Phase I/II
Gem92 Hybridon HIV gag AIDS 2nd generation Phase I
GTI 2051 Lorus Therapeutics Ribonucleotide 
reductase (R1)
Cancer PS DNA Phase I
Avi4557 AVI BioPharma CYP3A4 Metabolic redirection of approved drugs 3rd generation Phase IPage 4 of 6
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viruses in culture, including: RSV (respiratory syncytial
virus) [43], influenza virus [44], poliovirus [45] and HIV-
1 [46-48]. In the case of HIV-1, several specific mRNAs
have been successfully targeted for siRNA-mediated
silencing, including those that encode Gag, Pol, Vif and
the small regulatory proteins Tat and Rev. These studies
show that RNAi can effectively trigger the degradation of
not only viral mRNAs, but also genomic RNAs at both the
pre- and post-integration stages of the viral lifecycle. In
addition to targeting viruses directly, alternative strategies
have employed siRNAs that silence the expression of
essential host factors including Tsg101, required for
vacuolar sorting and efficient budding of HIV-1 progeny
[49], and the chemokine receptor CCR5, required as a co-
receptor for HIV-1 cell entry [50].
Conclusions
Currently, our understanding of the biological mecha-
nisms underlying RNAi lags behind the movement to
apply this technology to human diseases such as viral
infections. Some major technical hurdles need to be over-
come before siRNA-based anti-viral prophylaxis and treat-
ments move into the clinics. Especially, intracellular
delivery of siRNA needs to be greatly improved. The next
few years of research will indicate whether RNAi technol-
ogy will realize its potential as the next wave of Biochem-
ical Prevention and Treatment.
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